Frank Laukien - Bruker Chairman, CEO and Pres
| BRKR Stock | USD 75.71 0.50 0.66% |
Chairman
Dr. Frank H. Laukien, Ph.D., is Chairman of the Board, President, Chief Executive Officer of Bruker Corporationrationration. Dr. Laukien was our Chairman, President and Chief Executive Officer since February 1991 and is our largest stockholder. Dr. Laukien also serves as a director of various subsidiaries of Bruker, none of which are publiclytraded companies. Dr. Laukien served as a director of ALDA, an industry association formerly known as Analytical Life Sciences Systems Association, or ALSSA, for several terms in the past, and was ALSSA Chairman from 2002 to 2003. Dr. Laukien holds a BS degree in physics from the Massachusetts Institute of Technology, as well as a Ph.D. in chemical physics from Harvard University since 1991.
| Age | 64 |
| Tenure | 33 years |
| Professional Marks | Ph.D |
| Phone | 978 663 3660 |
| Web | https://www.bruker.com |
Bruker Management Efficiency
The company has return on total asset (ROA) of 0.0654 % which means that it generated a profit of $0.0654 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3029 %, meaning that it created $0.3029 on every $100 dollars invested by stockholders. Bruker's management efficiency ratios could be used to measure how well Bruker manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 9 records | CHAIRMAN Age | ||
| Curt Hartman | CONMED | 60 | |
| Miles White | Abbott Laboratories | 65 | |
| Thomas Burns | Glaukos Corp | 63 | |
| Mark Tryniski | CONMED | 60 | |
| DKeith Grossman | Nevro Corp | 64 | |
| Omar Ishrak | Medtronic PLC | 63 | |
| William Link | Glaukos Corp | 74 | |
| D Grossman | Nevro Corp | 59 | |
| Kevin Lobo | Stryker | 59 | |
Management Performance
| Return On Equity | 0.3 | ||||
| Return On Asset | 0.0654 |
Bruker Leadership Team
Elected by the shareholders, the Bruker's board of directors comprises two types of representatives: Bruker inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bruker. The board's role is to monitor Bruker's management team and ensure that shareholders' interests are well served. Bruker's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bruker's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frank Laukien, Chairman, CEO and Pres | ||
| Burkhard Prause, President and CEO, BEST | ||
| Collin DSilva, Pres Division | ||
| Gerald Herman, Interim CFO, Principal Accounting Officer | ||
| Juergen Srega, President of Bruker Daltonics Division and President of Bruker Calid Group | ||
| Falko Busse, President of the Bruker BioSpin Group and Executive Officer of the Company | ||
| Urban Faeh, Pres GmbH | ||
| Justin Ward, Senior Development | ||
| Stacey Desrochers, Treasurer Relations | ||
| Mark Munch, President of Bruker Nano Group | ||
| Brent JD, General Secretary |
Bruker Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bruker a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.3 | ||||
| Return On Asset | 0.0654 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.1 % | ||||
| Current Valuation | 12.05 B | ||||
| Shares Outstanding | 145.34 M | ||||
| Shares Owned By Insiders | 33.17 % | ||||
| Shares Owned By Institutions | 76.98 % | ||||
| Number Of Shares Shorted | 3.22 M | ||||
| Price To Earning | 67.10 X |
Pair Trading with Bruker
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bruker position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bruker will appreciate offsetting losses from the drop in the long position's value.Moving together with Bruker Stock
| 0.82 | EW | Edwards Lifesciences Corp | PairCorr |
Moving against Bruker Stock
| 0.68 | OM | Outset MedicalInc | PairCorr |
| 0.52 | PHG | Koninklijke Philips | PairCorr |
| 0.45 | DYNT | Dynatronics Fiscal Year End 26th of September 2024 | PairCorr |
The ability to find closely correlated positions to Bruker could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bruker when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bruker - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bruker to buy it.
The correlation of Bruker is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bruker moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bruker moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bruker can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bruker. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry. To learn how to invest in Bruker Stock, please use our How to Invest in Bruker guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for Bruker Stock analysis
When running Bruker's price analysis, check to measure Bruker's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bruker is operating at the current time. Most of Bruker's value examination focuses on studying past and present price action to predict the probability of Bruker's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bruker's price. Additionally, you may evaluate how the addition of Bruker to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |
Is Bruker's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bruker. If investors know Bruker will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bruker listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bruker is measured differently than its book value, which is the value of Bruker that is recorded on the company's balance sheet. Investors also form their own opinion of Bruker's value that differs from its market value or its book value, called intrinsic value, which is Bruker's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bruker's market value can be influenced by many factors that don't directly affect Bruker's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bruker's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bruker is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bruker's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.